Fizazi, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO-GU 2019, abstract 140.
Podcast: EGFR ex20ins gemuteerd NSCLC in de dagelijkse klinische praktijk - Sushil Badrising
nov 2024 | Longoncologie